用SGLT2i治疗的心力衰竭患者的排气分数减少:一个元分析
1Department of Cardiology, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan 646000, P.R. China.
Experimental and therapeutic medicine
|November 6, 2023
概括
-葡萄糖共运输体2抑制剂 (SGLT2i) 显著减少了心力衰竭 (HF) 的住院治疗和心血管死亡,患者减少了喷射分数. 这些好处适用于患有或没有糖尿病的患者,突出SGLT2i作为HF管理的关键疗法.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 内部医学 内部医学
背景情况:
- 心力衰竭 (HF) 与减少喷射率 (HFrEF) 是致病率和死亡率的主要原因.
- 确定HFrEF有效的治疗策略至关重要,特别是对于患有或没有糖尿病的患者.
研究的目的:
- 系统地审查和分析-葡萄糖共传输体2抑制剂 (SGLT2i) 对HFrEF患者心血管结局的影响.
- 评估SGLT2i对HF住院,心血管死亡和患者群体中所有原因死亡率的影响.
主要方法:
- 在HFrEF患者中进行了对随机对照试验 (RCT) 的系统审查,比较SGLT2i与安慰剂.
- 通过对PubMed,Web of Science和EMBASE数据库的全面搜索确定了研究,截至2021年7月.
- 使用固定或随机效应模型的几率比率 (OR) 和95%置信区间 (CI) 估计了聚合效应,并进行了灵敏度分析.
主要成果:
- 五个涉及HFrEF患者的RCT被纳入了元分析.
- 与安慰剂相比,SGLT2i显著降低了因HF/心血管死亡 (OR=0.72),心血管死亡 (OR=0.84),因HF住院 (OR=0.69) 和所有原因死亡率 (OR=0.79) 的住院风险.
- 在所有敏感性分析中,结果一致,这表明研究结果的可靠性.
结论:
- SGLT2抑制剂有效降低HF住院风险,心血管死亡和HFrEF患者的全因死亡率.
- SGLT2i的有益作用扩展到HFrEF患者,无论他们的糖尿病状况如何.
- 这些发现支持使用SGLT2i作为管理HFrEF的基础疗法.
更多相关视频
14:35Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
Published on: April 17, 2021
8.5K
07:24Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR
Published on: April 8, 2013
24.3K
相关概念视频
01:30Heart Failure V: Medical Management
9
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
9
01:29Heart Failure II: Pathophysiology
14
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
14
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
438
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
438
01:22Heart Failure VI: Adjunct Therapies
15
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
15
01:22Heart Failure Drugs: Diuretics
400
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
400
01:30Heart Failure IV: Classification and Diagnostic Evaluation
17
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
17